Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 6
Submit an article Journal homepage
338
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia

Richard R. FurmanDivision of Hematology and Medical Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY, USA; Correspondence[email protected]
,
Ying LuanPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
,
Elizabeth BilottiPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
&
Thorsten GraefPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Pages 1502-1505 | Received 31 Aug 2016, Accepted 06 Oct 2016, Published online: 26 Oct 2016
Supplemental material

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Download Zip (2.5 MB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.